Key result
Targeting the vWF-GPIbα axis emerges as a potential therapeutic strategy against thromboinflammation in ischemic stroke.
Why the study?
The thrombo-inflammatory nature of the VWF-platelet axis is increasingly recognized in cardiovascular pathologies, making it a potential therapeutic target to interfere with thrombosis and inflammation.
This review emphasizes the VWF-GPIbα axis as a critical thrombo-inflammatory pathway and a potential therapeutic target in ischemic stroke.
Answers are grounded in this paper and cite their sources.
Supports VWF-GPIbα inhibition as a stroke target; leaves open clinical efficacy pending trials.
von Willebrand factor (VWF) and platelets are key mediators of normal hemostasis. At sites of vascular injury, VWF recruits platelets via binding to the platelet receptor glycoprotein Ibα (GPIbα). Over the past decades, it has become clear that many hemostatic factors, including VWF and platelets, are also involved in inflammatory processes, forming intriguing links between hemostasis, thrombosis, and inflammation. The so-called "thrombo-inflammatory" nature of the VWF-platelet axis becomes increasingly recognized in different cardiovascular pathologies, making it a potential therapeutic target to interfere with both thrombosis and inflammation. In this review, we discuss the current evidence for the thrombo-inflammatory activity of VWF with a focus on the VWF-GPIbα axis and discuss its implications in the setting of ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Denorme et al. (2019) conducted a review in Ischemic stroke. VWF-GPIbα axis inhibitors and ADAMTS13 was evaluated. The von Willebrand factor-glycoprotein Ibα axis plays a crucial thromboinflammatory role in ischemic stroke, making it a potential therapeutic target to reduce both thrombosis and inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: